Genentech Inc. got the green light to expand its growth hormone market, as the FDA approved Nutropin (somatropin [rDNA origin] for injection) and Nutropin AQ (somatropin [rDNA origin] injection) for the long-term treatment of idiopathic short stature (ISS). (BioWorld Today)